Immunicom
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6048 Cornerstone Ct W Ste D, San Diego, ...Phone Number
(858) 546-7678Website
www.immunicom.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Immunicom
Immunicom specializes in innovative immunotherapy solutions, particularly through its Immunopheresis technology, which aims to enhance the quality of life for cancer patients while minimizing typical side effects. The company is focused on developing novel treatments for various diseases, including cancer, inflammatory, renal, and autoimmune conditions. With ongoing clinical trials at leading hospitals, Immunicom's therapies are designed to work outside the body by removing barriers that hinder the immune system. Their mission is to expedite patients' paths to a healthier future through transformative therapeutic devices.Explore more
Immunicom Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunicom your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Immunicom, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Immunicom is spiking on competitors!
Check if Immunicom has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Immunicom launches new products
Click to see if Immunicom had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Immunicom recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Immunicom
Funding: Get notified immidiatlly once Immunicom has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Immunicom
Find more new buyers
Compare Similar Companies to Immunicom
Compare insights from companies similar to Immunicom, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunicom is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunicom is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunicom.
Immunicom financials insights
Gather financial insights about Immunicom, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$5.5M
2019
Series B
$12.8M
2020
Debt
$350K
2021
Debt
$433K
Immunicom Tech Stack
A closer look at the technologies used by Immunicom
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Board of Directors
Left Company
Executive Move
Immunicom has announced that Annette Marleau, Chief Technology Officer, has left the organization to join Sigyn Therapeutics as Chief Scientific Officer.
Promotion
Executive Move
Immunicom has announced that Annette Marleau has been promoted from Vice President, Research & Development to the role of Chief Technology Officer.
Funding
Immunicom News & Media
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
SAN DIEGO--(BUSINESS WIRE)--Immunicom, Inc., a privately held clinical-stage biotechnology company with a transformative immuno-oncology platform, has been awarded $2 million by the National Cancer Institute (NCI) and National Institutes of Health (NIH) to initiate its first US-based clinical trial at the Baylor College of Medicine in Houston, Texas. The trial [NIH/NCI Grant 1R44CA261565-01A1], to be conducted in collaboration with Dr. Mothaffar F. Rimawi, Professor of Medicine/Oncology and ExeImmunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis® LW-02 Column is Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer
SAN DIEGO--(BUSINESS WIRE)--Immunicom, Inc., a privately held clinical-stage biotechnology company with a transformative immuno-oncology platform, presented data from its ongoing clinical investigation [NCT04004910] at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting. The trial data, detailed by principal investigator Prof. Piotr Wysocki, show that the Company’s Immunopheresis® LW-02 Column is a safe, promising immunotherapy that helps spur upregulation of a patient’s TNF-Immunicom Presents New Data at AACR 2022 of LW-02 Cartridge Immunopheresis® Therapy from Ongoing mTNBC Clinical Trial in Chemo-Refractory Patients
SAN DIEGO--(BUSINESS WIRE)--Immunicom, Inc., a clinical-stage biotechnology company developing a breakthrough technology platform for immuno-oncology, presented data from its ongoing clinical investigation, Protocol CP7-005 [NCT04004910], at the American Association for Cancer Research (AACR) Annual Conference in New Orleans. The trial data, presented by Principal Investigator, Prof. Piotr Wysocki, detailed continued encouraging data for the Company’s LW-02 Cartridge Immunopheresis® treatment uImmunicom Announces Addition of Key Industry Leaders to Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- #immunotherapy--Immunicom, Inc., a clinical-stage biotechnology company pioneering a first-of-its-kind technology platform for immuno-oncology, announced that Dr. Peter Farrell and Michael E. Lehman have joined the Company’s Board of Directors. Mr. Lehman, a seasoned corporate leader, brings financial and operational expertise with a focus on IPO readiness, while Dr. Farrell, founder and Chairman of ResMed, has a proven track record of recognizing and establishing ne
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunicom
Sign Up For FreeTo access detailed company insights
Immunicom specializes in innovative immunotherapy solutions, particularly through its Immunopheresis technology, which aims to enhance the quality of life for cancer patients while minimizing typical side effects. The company is focused on developing novel treatments for various diseases, including cancer, inflammatory, renal, and autoimmune condit... Read More
